Drug Trial Radar · NCT05584111
Oral Administration of STC-15 in Subjects With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Nov 15, 2022
Primary completion
Aug 30, 2024
Study completion Dec 22, 2024
Sponsor
- Lead sponsor
- STORM Therapeutics LTDIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies. Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs). The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers.
Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Cancer
Interventions
STC-15Drug
STC-15 oral capsules various dosing regimen in 3-week cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Related Treatment Emergent Adverse EventsTime frame: Screening through end of treatment, approximately 6 months
- Cmax (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on Cycle 1 Day 1 (C1D1)
- Tmax (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on C1D1
- Ctrough (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours Pre-dose on Cycle 2 Day 1
- Terminal Elimination Half Life (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on C1D1
- AUC (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
- Average Concentration (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C2D1.
- Systemic Clearance (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
- Volume of Distribution at Steady-state (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
- Accumulation Ratio From First Dose to Steady-state (PK)Time frame: For MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1 and C2D1.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Honor Health
Scottsdale, Arizona
The University of Texas MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.